ArticleCell death & disease2024
ALYREF promotes the metastasis of nasopharyngeal carcinoma by increasing the stability of NOTCH1 mRNA.
Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Epitranscriptomic control of cancer: the emerging roles of m⁵C and ac⁴C RNA modifications.Cell death discovery · 2026Review
- Epigenetic regulation in cancer metastasis.Discover oncology · 2026Review
- Epstein-Barr virus drives nasopharyngeal carcinoma metastasis via RNA mCell death and differentiation · 2026Article
- ALYREF-mediated RNA 5-methylcytosine modification promotes laryngeal cancer progression via stabilizing DDX11 mRNA.Scientific reports · 2026Article
- Hypoxia Triggers ALYREF-Mediated mThe Kaohsiung journal of medical sciences · 2026Article
- ALYREF regulates glycolysis and promotes the progression of endometrial cancer through mFrontiers in cell and developmental biology · 2026Article
- Multi-omics analysis reveals that ALYREF-mediated mCell death & disease · 2025Article
- RNA modifications in health and disease: from mechanistic insights to therapeutic applications.Precision clinical medicine · 2025Review
- RNA m5C methylation in cancer: mechanisms and biological impact.Oncogenesis · 2025Review
- Comprehensive analysis of ALYREF gene expression and its correlation with immunotherapy efficacy and circulating tumor cells in bladder cancer.Scientific reports · 2025Article
- Rewriting the Fate of Cancer: Epigenetic and Epitranscriptomic Regulators in the Metastatic Cascade.Biomolecules · 2025Review
- Article
- Epitranscriptomic Regulation of Hepatitis B Virus by RNA 5-Methylcytosine: Functions, Mechanisms, and Therapeutic Potential.Viruses · 2025Review
- m5C-modified circRREB1 promotes lung cancer progression by inducing mitophagy.Journal of experimental & clinical cancer research : CR · 2025Article
- m5C RNA methylation in cancer: from biological mechanism to clinical perspectives.European journal of medical research · 2025Review
- Identification of RNA processing factor LSM5 as a new adverse biomarker in nasopharyngeal carcinoma.Scientific reports · 2025Article
- NSUN2/ALYREF axis-driven mCancer immunology, immunotherapy : CII · 2025Article
- Biological functions of 5-methylcytosine RNA-binding proteins and their potential mechanisms in human cancers.Frontiers in oncology · 2025Review
- Epitranscriptomic mechanisms and implications of RNA mTheranostics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Approximately 70% of treatment failures in nasopharyngeal carcinoma (NPC) patients are attributed to distant metastasis, yet the underlying mechanisms remain unclear. RNA 5-methylcytosine (m5C) is an emerging regulatory modification that controls gene expression and plays a critical role in tumor progression. However, there is little information on the potential roles of RNA m5C modification in NPC metastasis. In this study, we found that the m5C reader Aly/REF export factor (ALYREF) is significantly upregulated in NPC, whereby its high expression is associated with metastasis and poor prognosis. ALYREF overexpression was found to promote tumor metastasis of NPC cells in vitro and in vivo. Mechanistically, m5C-modified NOTCH1 mRNA was identified as a target of ALYREF. Moreover, ALYREF was found to upregulate NOTCH1 expression by enhancing its RNA stability in an m5C modification-dependent manner, thereby promoting the activation of the NOTCH signaling pathway and facilitating NPC metastasis. Overall, our data reveal the crucial role of ALYREF in NPC metastasis and provide a potential therapeutic target for NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.